110707-74-9

Basic information

• Product Name: methyl 4-<<5-indol-3-yl>methyl>-3-methoxybenzoate
• Synonyms: methyl 4-<<5-indol-3-yl>methyl>-3-methoxybenzoate
• CAS NO: 110707-74-9
• Molecular Weight: 420.508
• Mol File: 110707-74-9.mol

Chemical Properties

• CAS DataBase Reference: methyl 4-<<5-indol-3-yl>methyl>-3-methoxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-<<5-indol-3-yl>methyl>-3-methoxybenzoate(110707-74-9)
• EPA Substance Registry System: methyl 4-<<5-indol-3-yl>methyl>-3-methoxybenzoate(110707-74-9)

Safety Data

• Hazardous Substances Data: 110707-74-9(Hazardous Substances Data)

Upstream product

• 136564-71-1 methyl 4-<<5-(benzyloxycarbonyl)indol-3-yl>methyl>-3-methoxybenzoate 
• 136564-69-7 1H-indole-5-carboxylic acid benzyl ester 
• 6053-81-2 cyclopentylmethylamine 
• 1670-81-1 1H-Indole-5-carboxylic acid 
• 70264-94-7 methyl 4-(bromomethyl)-3-methoxybenzoate 
• 110707-71-6 5-indole 
• 145889-27-6 methyl 4-<(5-carboxyindol-3-yl)methyl>-3-methoxybenzoate 

Downstream Products

• 142535-35-1 methyl 4-<<5--1-<2-(N,N-diethylcarbamoyl)ethyl>indol-3-yl>methyl>-3-methoxybenzoate 
• 142535-37-3 1-(2-Diethylcarbamoyl-ethyl)-3-[2-methoxy-4-(toluene-2-sulfonylaminocarbonyl)-benzyl]-1H-indole-5-carboxylic acid cyclopentylmethyl-amide 
• 142535-34-0 1-(1-Dimethylcarbamoyl-ethyl)-3-[2-methoxy-4-(toluene-2-sulfonylaminocarbonyl)-benzyl]-1H-indole-5-carboxylic acid cyclopentylmethyl-amide 
• 142535-26-0 3-[2-Methoxy-4-(toluene-2-sulfonylaminocarbonyl)-benzyl]-1-methyl-1H-indazole-5-carboxylic acid cyclopentylmethyl-amide 
• 142535-36-2 4-[5-(Cyclopentylmethyl-carbamoyl)-1-(2-diethylcarbamoyl-ethyl)-1H-indol-3-ylmethyl]-3-methoxy-benzoic acid 
• 142535-33-9 4-[5-(N-cyclopentylmethylcarbamoyl)-1-[1-(N,N-dimethylcarbamoyl)ethyl]indol-3-ylmethyl]-3-methoxybenzoic acid 
• 110707-77-2 methyl 4-<2-<5--2-(N-methylamino)phenyl>-2-(acetoxyimino)ethyl>-3-methoxybenzoate 
• 110707-79-4 methyl 4-<2-<5--2-(N-methylamino)phenyl>-2-(hydroxyimino)ethyl>-3-methoxybenzoate 
• 110707-78-3 methyl 4-<2-<5--2-(N-formyl-N-methylamino)phenyl>-2-oxoethyl>-3-methoxybenzoate 
• 110707-76-1 methyl 4-<<5--1-methylindazol-3-yl>methyl>-3-methoxybenzoate 
• 110707-82-9 4-[5-(Cyclopentylmethyl-carbamoyl)-1-methyl-1H-indazol-3-ylmethyl]-3-methoxy-benzoic acid 
• 145889-08-3 4-<<5-<(2-cyclopentylmethyl)carbamoyl>-1-(2-propenyl)indol-3-yl>methyl>-3-methoxy-N-<(2-methylphenyl)sulfonyl>benzamide 
• 145889-31-2 4-<<5-<(cyclopentylmethyl)carbamoyl>-1-(2-propanyl)indol-3-yl>methyl>-3-methoxybenzoic acid 
• 110707-73-8 methyl 4-<<5--1-methylindol-3-yl>methyl>-3-methoxybenzoate 

Relevant articles and documents

Substituted 3-(Phenylmethyl)-1H-indole-5-carboxamides and 1-(Phenylmethyl)indole-6-carboxamides as Potent, Selective, Orally Active Antagonists of the Peptidoleukotrienes

Substituted indole-5-caboxamides and indole-6-carboxamides have been found to be potent and selective antagonists of the peptidoleukotrienes.Initial derivatives of these series (4--1-methylindol-3-yl>methyl>-3-methoxy-N-

1,3,6-Trisubstituted indoles as peptidoleukotriene antagonists: Benefits of a second, polar, pyrrole substituent

1,6-Substituted and 3,5-substituted indoles and indazoles containing acylamino and N-arylsulfonyl amide appendages are potent antagonists of the peptidoleukotrienes LTD4 and LTE4. A compound from the 3,5-substituted indole series, N-[4-[[5-[[(cyclopentyloxy)carbonyl]amino]-1-methylindol-3- yl]methyl]-3-methoxybenzoyl]-2-methyl-benzenesulfonamide (ICI 204,219), is undergoing clinical evaluation for asthma. Two new elements of structural diversity were introduced to this series of antagonists. An investigation of pyrrole substituents in the 1,6-substituted indoles demonstrated that substitution at C-2 was detrimental to biological activity, but the incorporation of hydrophilic groups at C-3 was beneficial. The introduction of a propionamide moiety at C-3 enhanced activity by 1 order of magnitude; N- [4-[[6-(cyclopentylacetamido)-3-[2-(N-methylcarbamoyl)ethyl]indol-1- yl]methyl]-3-methoxybenzoyl]benzenesulfonamide (15c) has a pK(B) of 10.7 at the LTD4 receptor on guinea pig trachea. Modifications of the acylamino portion of the disubstituted antagonists demonstrated that a transposition of the amide CO and NH atoms was viable. N-Cyclopentylmethyl amides in both the 1,6- and 3,5-disubstituted indole series were 1 order of magnitude less potent than the corresponding cyclopentylacetamides. In both series this potency loss could be regained by the incorporation of a propionamide substituent at either C-3 or N-1, respectively. For example, N-[4-[[6-[N- (cyclopentylmethyl)carbamoyl]-3-[2-(pyrrolidin-1-ylcarbonyl)ethyl]indol-1- yl]methyl]-3-methoxybenzoyl]-2-methylbenzenesulfonamide (39c) has a pK(B) of 9.5.

Indole and indazole keto sulphones as leukotriene antagonists

This invention provides a series of novel keto sulfones of formula I STR1 in which the group =A-- is selected from =C(Ra)-- and =N-- and the other radicals have the meanings defined in the following specification. The compounds of formula I are leukotriene antagonists. The invention also provides pharmaceutically acceptable salts of the formula I compounds; pharmaceutical compositions containing the formula I compound, or their salts, for use in the treatment of, for example, allergic or inflammatory diseases, or endotoxic or traumatic shock conditions; and processes for the manufacture of the formula I compounds, as well as intermediates for use in such manufacture.